Table II

Engraftment capacity of mobilized BM LT-HSC

4 wk8 wk12–18 wk
Cell #Frequencyreconstitution(#/total)Average chimerism(range)engraftment type(#/reconstituted)Frequencyreconstitution(#/total)Average chimerism(range)engraftment type(#/reconstituted)Frequencyreconstitution(#/total)Average chimerism(range)engraftment type(#/reconstituted)
Untreated
 BM LT-HSC
50100% (8/8)11.07% (2.3–22.7%)
 M + L (8/8)100% (7/7)29.2% (6.7–56.9%)
 M + L (7/7)100% (7/7)30.2% (6.2–56.2%)
 M + L (7/7)
D2 Cy/G mobilized
 BM LT-HSC
5046% (7/15)2.9% (0.2–12.5%)
 M + L (7/7)40% (6/15)6.1% (0.4–26.8%)
 M + L (4/6), L only (2/6)40% (6/15)4.6% (0.1–18.1%)
 M + L (4/6), L only (2/6)
  • LT-HSC (Lin/c-Kit+/Sca-1+/Thy1.1int/Flk-2) were double FACS–sorted from BM of untreated C57BL/6-Ly5.1 donor mice or from mice subjected to the D2 Cy/G mobilization treatment and tested for their engraftment capacities by limited dilution competitive reconstitution assays. 50 cells were transplanted into lethally irradiated congenic C57BL/6-Ly5.2 recipient mice together with 3 × 105 Ly5.2+ helper BM cells. Recipient mice were considered to be reconstituted by Ly5.1+ donor cells if the frequencies of Ly5.1+ donor-derived myeloid (M, Gr-1+, or Mac-1+) or lymphoid (L, B220+, or CD3+) cells detected in the peripheral blood at the indicated times after transplantation were greater than background levels (≥0.1% as determined by parallel analysis of untransplanted control C57BL/6-Ly5.2 mice). M + L indicates multilineage reconstitution.